eli lilly & co. - LLY

LLY

Close Chg Chg %
729.58 23.79 3.26%

Closed Market

753.37

+23.79 (3.26%)

Volume: 5.16M

Last Updated:

Nov 20, 2024, 3:59 PM EDT

Company Overview: eli lilly & co. - LLY

LLY Key Data

Open

$735.89

Day Range

735.46 - 757.37

52 Week Range

562.00 - 972.53

Market Cap

$692.74B

Shares Outstanding

949.32M

Public Float

850.67M

Beta

0.43

Rev. Per Employee

N/A

P/E Ratio

79.83

EPS

$9.17

Yield

68.93%

Dividend

$1.30

EX-DIVIDEND DATE

Nov 15, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

4.96M

 

LLY Performance

1 Week
 
-2.21%
 
1 Month
 
-20.51%
 
3 Months
 
-23.41%
 
1 Year
 
21.40%
 
5 Years
 
527.99%
 

LLY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About eli lilly & co. - LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

LLY At a Glance

Eli Lilly & Co.
Lilly Corporate Center
Indianapolis, Indiana 46285
Phone 1-317-276-2000 Revenue 34.12B
Industry Pharmaceuticals: Major Net Income 5.24B
Sector Health Technology 2023 Sales Growth 19.56%
Fiscal Year-end 12 / 2024 Employees 43,000
View SEC Filings

LLY Valuation

P/E Current 79.826
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 100.477
Price to Sales Ratio 15.43
Price to Book Ratio 51.376
Price to Cash Flow Ratio 124.182
Enterprise Value to EBITDA 46.313
Enterprise Value to Sales 16.086
Total Debt to Enterprise Value 0.046

LLY Efficiency

Revenue/Employee 793,583.721
Income Per Employee 121,869.767
Receivables Turnover 3.01
Total Asset Turnover 0.601

LLY Liquidity

Current Ratio 0.943
Quick Ratio 0.731
Cash Ratio 0.107

LLY Profitability

Gross Margin 79.246
Operating Margin 30.258
Pretax Margin 19.208
Net Margin 15.357
Return on Assets 9.235
Return on Equity 48.926
Return on Total Capital 14.558
Return on Invested Capital 19.238

LLY Capital Structure

Total Debt to Total Equity 234.177
Total Debt to Total Capital 70.076
Total Debt to Total Assets 39.411
Long-Term Debt to Equity 170.08
Long-Term Debt to Total Capital 50.895
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Eli Lilly & Co. - LLY

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
24.54B 28.32B 28.54B 34.12B
Sales Growth
+9.95% +15.40% +0.79% +19.56%
Cost of Goods Sold (COGS) incl D&A
5.48B 7.31B 6.63B 7.08B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.32B 1.55B 1.52B 1.53B
Depreciation
895.70M 918.80M 942.80M 1.02B
Amortization of Intangibles
428.20M 628.80M 579.70M 505.60M
COGS Growth
+16.14% +33.36% -9.34% +6.82%
Gross Income
19.06B 21.01B 21.91B 27.04B
Gross Income Growth
+8.29% +10.23% +4.31% +23.41%
Gross Profit Margin
+77.66% +74.18% +76.77% +79.25%
2020 2021 2022 2023 5-year trend
SG&A Expense
12.21B 13.46B 13.63B 16.72B
Research & Development
6.09B 7.03B 7.19B 9.31B
Other SG&A
6.12B 6.43B 6.44B 7.40B
SGA Growth
+3.37% +10.25% +1.29% +22.63%
Other Operating Expense
- - - -
-
Unusual Expense
565.50M 1.84B 1.35B 3.79B
EBIT after Unusual Expense
6.28B 5.71B 6.93B 6.54B
Non Operating Income/Expense
1.31B 789.80M 210.60M 500.40M
Non-Operating Interest Income
33.00M 25.40M 62.80M 173.60M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
359.60M 339.80M 331.60M 485.90M
Interest Expense Growth
-10.23% -5.51% -2.41% +46.53%
Gross Interest Expense
359.60M 339.80M 331.60M 485.90M
Interest Capitalized
- - - -
-
Pretax Income
7.23B 6.16B 6.81B 6.55B
Pretax Income Growth
+37.30% -14.86% +10.57% -3.70%
Pretax Margin
+29.46% +21.74% +23.85% +19.21%
Income Tax
1.04B 573.80M 561.60M 1.31B
Income Tax - Current - Domestic
520.30M 910.10M 2.20B 3.04B
Income Tax - Current - Foreign
650.40M 466.00M 547.70M 613.00M
Income Tax - Deferred - Domestic
(117.90M) (976.90M) (2.11B) (2.38B)
Income Tax - Deferred - Foreign
(16.60M) 174.60M (78.20M) 34.20M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.19B 5.58B 6.24B 5.24B
Minority Interest Expense
- - - -
-
Net Income
6.19B 5.58B 6.24B 5.24B
Net Income Growth
+33.55% -9.88% +11.88% -16.08%
Net Margin Growth
+25.24% +19.71% +21.88% +15.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.19B 5.58B 6.24B 5.24B
Preferred Dividends
- - - -
-
Net Income Available to Common
6.19B 5.58B 6.24B 5.24B
EPS (Basic)
6.824 6.1543 6.9253 5.8215
EPS (Basic) Growth
+36.99% -9.81% +12.53% -15.94%
Basic Shares Outstanding
907.63M 906.96M 901.74M 900.18M
EPS (Diluted)
6.7876 6.1224 6.9032 5.8015
EPS (Diluted) Growth
+36.94% -9.80% +12.75% -15.96%
Diluted Shares Outstanding
912.50M 911.68M 904.62M 903.28M
EBITDA
8.17B 9.10B 9.80B 11.85B
EBITDA Growth
+16.40% +11.28% +7.78% +20.91%
EBITDA Margin
+33.31% +32.12% +34.35% +34.73%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 1,012.711
Number of Ratings 31 Current Quarters Estimate 5.472
FY Report Date 12 / 2024 Current Year's Estimate 13.261
Last Quarter’s Earnings 1.18 Median PE on CY Estimate N/A
Year Ago Earnings 6.32 Next Fiscal Year Estimate 22.518
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 3 15 26
Mean Estimate 5.47 5.15 13.26 22.52
High Estimates 5.82 5.60 13.75 29.06
Low Estimate 5.32 4.90 13.03 16.88
Coefficient of Variance 2.46 7.60 1.43 9.83

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 20 20 19
OVERWEIGHT 5 5 5
HOLD 5 6 5
UNDERWEIGHT 1 0 1
SELL 0 1 0
MEAN Overweight Overweight Overweight

Insider Actions for Eli Lilly & Co. - LLY

Date Name Shares Transaction Value
Sep 13, 2024 Daniel M. Skovronsky EVP, CSO & Pres. LRL & LLY Imm 123,627 Bona fide gift 0.00
Sep 13, 2024 Daniel M. Skovronsky EVP, CSO & Pres. LRL & LLY Imm 117,903 Bona fide gift 0.00
Jul 17, 2024 Mary Lynne Hedley Director 1,513 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $950.46 per share 1,438,045.98
Jul 17, 2024 Ralph Alvarez Director 54,150 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $950.46 per share 51,467,409.00
Jul 17, 2024 Gabrielle G. Greene-Sulzberger Director 2,165 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $950.46 per share 2,057,745.90
Jul 17, 2024 Juan Ricardo Luciano Director 15,754 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $950.46 per share 14,973,546.84
Jul 17, 2024 Kimberly H. Johnson Director 2,664 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $950.46 per share 2,532,025.44
Jul 12, 2024 Lilly Endowment, Inc. 97,113,827 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $938.03 per share 91,095,683,140.81
Jul 12, 2024 Lilly Endowment, Inc. 96,943,810 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $944.9 per share 91,602,206,069.00
Jul 12, 2024 Lilly Endowment, Inc. 96,947,310 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $944.06 per share 91,524,077,478.60
Jul 12, 2024 Lilly Endowment, Inc. 96,956,595 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $943.09 per share 91,438,795,178.55
Jul 12, 2024 Lilly Endowment, Inc. 96,961,114 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $941.96 per share 91,333,490,943.44
Jul 12, 2024 Lilly Endowment, Inc. 96,963,312 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $940.87 per share 91,229,871,361.44
Jul 12, 2024 Lilly Endowment, Inc. 96,992,459 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $939.95 per share 91,168,061,837.05
Jul 12, 2024 Lilly Endowment, Inc. 97,085,341 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $939.11 per share 91,173,814,586.51
Jul 12, 2024 Lilly Endowment, Inc. 97,128,743 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $936.9 per share 90,999,919,316.70
Jul 10, 2024 Lilly Endowment, Inc. 97,155,910 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $924.71 per share 89,841,041,536.10
Jul 10, 2024 Lilly Endowment, Inc. 97,154,410 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $926.23 per share 89,987,329,174.30
Jul 10, 2024 Lilly Endowment, Inc. 97,154,010 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $927.3 per share 90,090,913,473.00
Jul 10, 2024 Lilly Endowment, Inc. 97,153,810 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $928.25 per share 90,183,024,132.50

Eli Lilly & Co. in the News

Markets

Meet Disney's newly elected board

Disney CEO Bob Iger will be working closely with his newly elected board, which boasts a handful of current and former Fortune 500 executives and some niche corporate insiders.